The therapeutic cooperation between STIL siRNA and cisplatin observed in the preclinical cancer models (Figure 2) raised the possibility that STIL depletion enhances the sensitivity of ovarian cancer cells to DNA damaging agents. Here, STIL is linked to ovarian cancer.